Overview

This is an international, first-in-human, multicenter, open-label Phase 1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patients with B-Cell non-Hodgkin lymphoma.

Eligibility

Main Inclusion criteria

• Patients with advanced histologically confirmed, documented CD20+ B-cell non-Hodgkin's lymphoma (NHL) including the following types defined by WHO 2016: Diffuse Large B Cell Lymphoma (DLBCL); high grade; thymic; Follicular Lymphoma (FL); Mantle cell lymphoma (MCL); Marginal zone lymphoma (MZL)
• Relapsed, progressive and/or refractory disease without established alternative therapy
• Must have received at least 2 prior systemic therapies including at a minimum anti-CD20 antibody therapy (e.g., rituximab) potentially in combination with chemotherapy and/or relapsed after autologous stem cell rescue.
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
• Adequate organ and hematological function
• Able to provide a fresh biopsy from a safely accessible site (or historical biopsy), per investigator determination.

Main Exclusion Criteria

• Patients with another invasive malignancy in the last 2 years
• Prior chemotherapy, immunotherapy or other anti-cancer therapy within less than 4 weeks before study drug administration.
• Autologous stem cell transplant or treatment with CAR-T (Chimeric Antigen Receptor T-Cell) cell therapy within 100 days prior to first dose of study drug
• Subjects with brain or subdural metastases are not eligible, nor those with history of central nervous system (CNS) lymphoma
• Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease.
• Known history of infection with human immunodeficiency virus (HIV) or hepatitis B or C
• Major surgery within 4 weeks before the first dose of study drug
• Comorbidities including diabetes, cardiovascular diseases, immunodeficiencies/autoimmune condition
• Pregnant / breastfeeding woman